Guggenheim maintains Buy on Pfizer, lowers target to $35
Guggenheim analyst Vamil Divan has maintained a Buy rating on Pfizer, lowering the price target from $36 to $35. The adjustment indicates a revised valuation while keeping a positive outlook on the stock.
*this image is generated using AI for illustrative purposes only.
Guggenheim analyst Vamil Divan has maintained a Buy rating on Pfizer while lowering the price target from $36 to $35. The adjustment reflects a revised valuation outlook for the pharmaceutical company as the firm assesses its current market position.
The decision to retain the Buy rating suggests confidence in the company's long-term prospects despite the reduction in the price target. No specific changes to financial guidance or operational expectations were detailed in this update.
Analyst Details
| Analyst | Firm | Rating | Price Target |
|---|---|---|---|
| Vamil Divan | Guggenheim | Buy | $35 |
Historical Stock Returns for Pfizer
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.34% | -3.02% | +2.91% | -1.42% | -13.89% | -17.38% |
What factors are driving the revised valuation outlook for Pfizer?
How might Pfizer's current market position influence its long-term growth strategy?
Are there upcoming product launches or pipeline developments that could offset the reduced price target?
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
